- Pharvaris (PHVS, Financial) presented positive clinical data for deucrictibant in treating bradykinin-mediated angioedema.
- Deucrictibant shows efficacy in both prophylactic and on-demand treatment settings.
- The company's extended-release formulation supports once-daily dosing with sustained therapeutic exposure.
Pharvaris (PHVS), a biopharmaceutical company, has showcased encouraging clinical data for its novel oral bradykinin B2 receptor antagonist, deucrictibant, at the 14th C1-Inhibitor Deficiency Workshop. The findings highlight the drug’s efficacy in treating bradykinin-mediated angioedema, including hereditary angioedema (HAE), through both prophylactic and on-demand approaches.
In long-term prophylaxis, deucrictibant maintained a reduced attack rate for over 18 months, significantly improving patients' quality of life. The drug's new extended-release (XR) formulation offers 24-hour therapeutic coverage, facilitating once-daily dosing. For on-demand treatment, a single dose of deucrictibant effectively managed 95-100% of HAE attacks without symptom recurrence. The median time to symptom relief was a swift 1.1 hours, with 92.9% of upper airway attacks requiring only one dose.
The company has also validated a novel biomarker assay for bradykinin-mediated angioedema, potentially broadening the treatment options for this condition. Pharvaris is advancing deucrictibant into pivotal Phase 3 studies, with significant data readouts anticipated in the next 18 months, further supporting its development as a dual-use therapy for HAE management.
